Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports:: A double blind, placebo-controlled study

被引:125
作者
Longobardi, S
Keay, N
Ehrnborg, C
Cittadini, A
Rosén, T
Dall, R
Boroujerdi, MA
Bassett, EE
Healy, ML
Pentecost, C
Wallace, JD
Powrie, J
Jorgensen, JO
Sacca, L
机构
[1] Univ Naples Federico II, Dept Clin Med & Cardiovasc Sci, I-80131 Naples, Italy
[2] St Thomas Hosp, Dept Endocrinol, London SE1 7EH, England
[3] Sahlgrenska Hosp, Res Ctr Endocrinol & Metab, S-41345 Gothenburg, Sweden
[4] Aarhus Community Hosp, Dept Endocrinol, Aarhus, Denmark
[5] Univ Kent, Inst Math & Stat, Canterbury CT2 7NF, Kent, England
关键词
D O I
10.1210/jc.85.4.1505
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of GH on bone remodeling in healthy adults have not been systematically investigated. An analysis of these effects might provide insights into GH physiology and might yield data useful for the detection of GH doping in sports. The aim of this study was to evaluate the effects of GH administration on biochemical markers of bone and collagen turnover in healthy volunteers. Ninety-nine healthy volunteers of both sexes were enrolled in a multicenter, randomized, double blind, placebo-controlled study and assigned to receive either placebo (40 subjects) or recombinant human GH (0.1 IU/kg day in 29 subjects and 0.2 IU/kg day in 30 subjects). The treatment duration was 28 days, followed by a 56-daywash-out period. The biochemical markers evaluated were the bone formation markers osteocalcin and C-terminal propeptide of type I procollagen, the resorption marker type I collagen telopeptide, and the soft tissue marker procollagen type III. All variables increased on days 21 and 28 in the two active treatment groups us. levels in both the baseline (P < 0.01) and placebo (P < 0.01) groups. The increment was more pronounced in the 0.2 IU/kg day group and remained significant on day 84 for procollagen type III (from 0.53 +/- 0.13 to 0.61 +/- 0.14 kU/L; P < 0.02) and osteocalcin (from 12.2 +/- 2.9 to 14.6 +/- 3.6 UG/L; P < 0.02), whereas levels of C-terminal propeptide of type I procollagen and type I collagen telopeptide declined after day 42 and were no longer significantly above baseline on day 84 (from 3.9 +/- 1.2 to 5.1 +/- 1.5 mu g/L and from 174 +/- 60 to 173 +/- 53 mu g/L, respectively). Gender-related differences were observed in the study; females were less responsive than males to GH administration with respect to procollagen type III and type I collagen telopeptide (P < 0.001). In conclusion, exogenous GH administration affects the biochemical parameters of bone and collagen turnover in a dose- and gender-dependent manner. As GH-induced modifications of most markers, in particular procollagen type III and osteocalcin, persist after GH withdrawal, they may be suitable markers for detecting GH abuse.
引用
收藏
页码:1505 / 1512
页数:8
相关论文
共 17 条
[1]   Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency [J].
Bollerslev, J ;
Moller, J ;
Thomas, S ;
Djoseland, O ;
Christiansen, JS .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1996, 135 (06) :666-671
[2]  
BRIXEN K, 1990, J BONE MINER RES, V5, P609
[3]   Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women [J].
Burman, P ;
Johansson, AG ;
Siegbahn, A ;
Vessby, B ;
Karlsson, FA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :550-555
[4]   INDUCTION OF IMMUNOREACTIVE SOMATOMEDIN-C IN HUMAN-SERUM BY GROWTH-HORMONE - DOSE-RESPONSE RELATIONSHIPS AND EFFECT ON CHROMATOGRAPHIC PROFILES [J].
COPELAND, KC ;
UNDERWOOD, LE ;
VANWYK, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1980, 50 (04) :690-697
[5]   Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle [J].
Gorai, I ;
Taguchi, Y ;
Chaki, O ;
Kikuchi, R ;
Nakayama, M ;
Yang, BC ;
Yokota, SP ;
Minaguchi, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (02) :326-332
[6]  
HO KKY, 1992, J BONE MINER RES, V7, P821
[7]   Skeletal effects of two years of treatment with low physiological doses elf recombinant human growth hormone (GH) in patients with adult-onset GH deficiency [J].
Janssen, YJH ;
Hamdy, NAT ;
Frölich, M ;
Roelfsema, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (06) :2143-2148
[8]   Growth hormone and the acquisition of bone mass [J].
Johannsson, G ;
Bengtsson, BÅ .
HORMONE RESEARCH, 1997, 48 :72-77
[9]   LOW PLASMA-LEVELS OF INSULIN-LIKE GROWTH FACTOR-I (IGF-1) IN MALE-PATIENTS WITH IDIOPATHIC OSTEOPOROSIS [J].
LJUNGHALL, S ;
JOHANSSON, AG ;
BURMAN, P ;
KAMPE, O ;
LINDH, E ;
KARLSSON, FA .
JOURNAL OF INTERNAL MEDICINE, 1992, 232 (01) :59-64
[10]   Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients [J].
Longobardi, S ;
Di Rella, F ;
Pivonello, R ;
Di Somma, C ;
Klain, M ;
Maurelli, L ;
Scarpa, R ;
Colao, A ;
Merola, B ;
Lombardi, G .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1999, 22 (05) :333-339